Bipolar Disorder (BPD) in Pregnancy: Predictors of Morbidity

Pregnancy Clinical Trial

Official title:

Bipolar Disorder in Pregnancy: Predictors of Morbidity

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00864370
• Other study ID #: IRB00046058
• Secondary ID: R01MH071531Bipol
• Status: Completed
• Phase: N/A
• First received: February 25, 2009
• Last updated: November 12, 2013
• Start date: May 2005
• Est. completion date: June 2013

Study information

• Verified date: November 2013
• Source: Emory University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Very little is known about the impact of pregnancy and the postpartum period on BPD. As a result, the investigators have little evidence on which to base treatment guidelines. The main goal of this study is to help fill this gap by finding the risk factors for BPD relapse during pregnancy and the postpartum period.

The risk factors that the investigators will study include:

1. the severity of illness in the past

2. the type and severity of both recent and past stressors

3. any treatments received during pregnancy and the postpartum period.

Other goals of the study are:

1. to see what effect, if any, illness or any medicines taken during pregnancy have on the baby's well-being at delivery

2. to see how pregnancy alters the way the body clears any medicines taken for BPD

3. to see how much of these medicines babies are exposed to during pregnancy or breast-feeding.

The investigators believe that the information gathered in this study will lead to new treatment guidelines for BPD during pregnancy and the postpartum period that will improve outcomes for pregnant women with BPD and their babies.

Description:

Despite the significant morbidity of bipolar disorder (BPD) and its high prevalence during the childbearing years, remarkably little is known about the impact of the female reproductive life cycle on BPD. Clinicians lack evidence-based guidelines for the perinatal management of BPD. The proposal addresses an understudied area with considerable public health implications for the estimated 100,000 women with BPD who conceive each year in the US.

The broad goal of this project is to delineate the clinical, psychosocial, and in particular, pharmacologic predictors of BPD recurrence during pregnancy. Preliminary findings suggest that inadequate treatment is a particularly robust predictor of prenatal BPD recurrence. Consequently, a specific emphasis will be placed on investigating the recurrence risk associated with suboptimal pharmacotherapy occurring as a result of medication discontinuation or declining drug concentrations secondary to increased prenatal clearance.

A prospective cohort design with monthly assessments will be implemented in a collaborative investigation between two of the leading perinatal psychiatry academic centers in the US with specific expertise in mood disorders research during pregnancy. The specific aims are 1) to quantify the risks for both syndromal and subsyndromal prenatal BPD illness associated with suboptimal pharmacotherapy while controlling for the severity of the previous course of illness and recent psychosocial stressors, 2) to examine the association of maternal prenatal BPD morbidity and psychotropic exposure with infant outcome at delivery thereby filling a current void and rounding out the requisite facets of the clinical risk/benefit assessment, and 3) to conduct pharmacokinetic (PK) modeling in an effort to delineate pregnancy-associated changes in drug clearance and provide initial reliable estimates of fetal drug exposure.

Study results will represent an incremental advance that: 1) elucidates risk factors for BPD morbidity during pregnancy; 2) contributes clinically relevant data to establish therapeutic guidelines for BPD during pregnancy; and 3) serve as a basis for preventive strategies aimed at optimizing maternal and infant outcome. Furthermore, the novel PK data will expand our understanding of prenatal drug metabolism, and the project will establish a cohort of children of women with BPD with detailed prospective prenatal histories.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 237
• Est. completion date: June 2013
• Est. primary completion date: January 2011
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• Medically healthy adult women (ages 18-45) fulfilling DSM-IV criteria for BPD of any subtype who are = 16 weeks gestation dated by last menstrual period (LMP)

• Able to give informed consent and comply with study procedures

Exclusion Criteria:

• Actively suicidal or homicidal

• Active substance use disorder within 6 months prior to enrollment

• Positive urine drug screen

• Hematocrit < 30

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Bipolar Disorder
• Pregnancy

Locations

Country	Name	City	State
United States	Emory University Department of Psychiatry & Behavioral Sciences	Atlanta	Georgia

Sponsors (3)

Lead Sponsor	Collaborator
Emory University	Massachusetts General Hospital, The Cleveland Clinic

Country where clinical trial is conducted

United States, 

References & Publications (2)

Johnson KC, LaPrairie JL, Brennan PA, Stowe ZN, Newport DJ. Prenatal antipsychotic exposure and neuromotor performance during infancy. Arch Gen Psychiatry. 2012 Aug;69(8):787-94. — View Citation

Newport DJ, Baldessarini RJ, Knight BT, Fernandez SV, Morris NJ, Viguera AC, Stowe ZN. Comparison of women with confirmed versus presumably misdiagnosed bipolar disorder. J Clin Psychiatry. 2012 Feb;73(2):242-6. doi: 10.4088/JCP.11m06936. Epub 2011 Dec 27 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine if psychiatric morbidity among pregnant women with BPD is greatest for those who receive suboptimal pharmacotherapy, have a more severe past illness-course, or have experienced recent psychosocial stressors.		Nine months	No

External Links

•   Emory Women's Mental Health Program